RE:RE:RE:New Press Release - Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS In simple terms, Onc has clear proven veryfied " biomarker", data.
Meaning mutiple very early oppotunities to know if the Pea treatment would work for each individual, prior to a long treatment cycle.
They have positive efficacy data with 3 of the 4 Goblet trials with Roche.
All that is left to do is sign a deal.
Why so long?
Not one person posting on here can know that answer for sure.including myself.
however, my opinion
imho
1. The removal of PanCan trial ( which was identified as a PanCan Gov funding issue), blindsided any negotiation progress.Meaning a whole new game.
2. An obvious difference between what Onc mangement & any potential suitors feel a $$ vale should be.
Moving forward.
Any business deal takes a lot longer the more variables there are.
The Onc side of the equation has many factors that we know, continue to change as studies mature.
The potential B.D. Pharma opportunities? Not an unlimited amount of variables, but not something quantified. Simply because we have no idea how many or which pharma companies they are in talk with.
Again, save the " no talks nonsense", they have stated mutiple times they are in discussions. In a post deal or failure audit, those details will be made public.
Assuming there are no talks, that would put all executive & board of directors at risk of many legal & civl charges.
They are all very well educated, huge pedigree of experience. Not likely any would risk their individual status to perpetuate a fraud.
So...yes there are talks. With more than one pharma.
Moving to a decision?
The PanCan cancellation was 100% outside of onc control & tottaly through a wrench into any existing " talks".
My opinion Onc should openly put itself up for sale.